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Abstract A commercial antibody (clone 22) directed against
the apoptosis-linked gene 2 (alg2, pdcd6) encoded protein has
been used by several groups. Up-regulated expression of the
antigen was observed in primary tumours and in metastatic
tissue and also during rat brain ischemia. Furthermore, antigen
down-regulation was found in human atherosclerotic plaques.
Recently, we found that the clone 22 antibody does not recog-
nise ALG-2. In the present study the antigen of the clone 22
antibody was identi¢ed as the heat shock protein 90 (HSP90)
co-chaperone protein p23, identical to the cytosolic prostaglan-
din E2 synthase, by immunoprecipitation followed by tryptic
in-gel digests and mass spectrometry of the puri¢ed peptides.
Moreover, the heterogeneous ribonuclear protein A2/B1 was
found to be a part of the p23 co-immunoprecipitated protein
complex.
3 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
In a recent study we found that the clone 22 Becton Dick-
inson (BD) Transduction Laboratories monoclonal antibody
assumed to recognise apoptosis-linked gene 2 (ALG-2) did not
detect a protein with the correct size [1]. Since part of the
published research on ALG-2 therefore was based on false
assumptions, we intended to identify the antigen of the clone
22 antibody. In this paper we have identi¢ed the antigen as
the heat shock protein 90 (HSP90) co-chaperone p23 that has
recently been shown to be the cytosolic prostaglandin (PG) E2
synthase (cPGES), one of the enzymes downstream of the
cyclooxygenases (COX-1 and COX-2) [2]. COX-1 and COX-
2 deliver the prostanoid precursor PGH2 for the enzymes,
which catalyse the synthesis of thromboxanes, prostacyclines,
and PGs. The COXs are functionally coupled to two di¡erent
types of PGE2 synthases. COX-1 is coupled to cPGES, where-
as COX-2 primarily couples to the membrane bound PGES
(mPGES). By their contribution to the synthesis of potent
biological mediators, the COXs are known to be involved in
several human pathologies including pain, in£ammation, few-
er, thrombosis, cancer, and neurological disorders such as
Alzheimer’s and Parkinson’s diseases (see [3]).
Based on our ¢nding that the BD clone 22 antibody recog-
nises p23 but not ALG-2, and the previous published papers
describing features of the antigen to the clone 22 antibody, we
suggest that p23 may play a role in several pathologies includ-
ing cancer, ischemia and atherosclerosis.
2. Experimental
2.1. Reagents and antibodies
A⁄nity puri¢ed rabbit anti-ALG-2 antibodies were produced in our
laboratory as previously described [1]. Horseradish peroxidase-conju-
gated goat anti-mouse immunoglobulins and goat anti-rabbit immu-
noglobulins were purchased from DakoCytomation, Glostrup, Den-
mark. The mouse monoclonal IgG1 anti-ALG-2, clone 22, the mouse
monoclonal IgG1 anti-p23, clone 16, and the mouse monoclonal IgG1
anti-Fas/CD95, clone 13, were from BD Transduction Laboratories
(BD Biosciences, San Jose, FL, USA). The mouse monoclonal IgG1
anti-p23, clone JJ3 was kindly provided by David Toft, Mayo Clinic,
Rochester, MN, USA. The mouse monoclonal IgG3 anti-Fas/CD95/
APO-1, clone APO-1-3 was a kind gift from Peter Krammer,
Deutsches Krebsforschungszentrum, Heidelberg, Germany. Protein-
G Sepharose Fast Flow was purchased from Amersham Biosciences,
Freiburg, Germany. Acetonitrile was from Rathburn Chemicals, Wal-
kerburn, Scotland. Tri£uoroacetic acid was from Pierce, Rockford,
IL, USA. Coomassie Brilliant Blue G, dithiothreitol, iodoacetamide,
and 4-hydroxy-K-cyanocinnamic acid were from Sigma, St. Louis,
MO, USA, WZiptips were from Millipore, Bedford, MA, USA, the
modi¢ed porcine trypsin was from Promega, Madison, WI, USA, and
ultragrade ammonium bicarbonate was from Fluka, Buchs, Switzer-
land. All other reagents were of analytical grade.
2.2. Apoptosis induction, Jurkat cell lysate preparation and
immunoblotting
Jurkat-E6 cells were maintained in RPMI 1640 medium (Invitrogen
Corp., Carlsbad, USA) containing 10% heat inactivated fetal calf
serum, penicillin and streptomycin (Invitrogen Corp.) at 37‡C in a
5% CO2 atmosphere. Apoptosis of Jurkat-E6 cells was induced by
cross-linking of the CD95 receptor using the anti-APO-1-3 antibody
along with 10 ng/ml of protein A for 2 or 4 h.
To prepare Jurkat-E6 cell lysates for immunoprecipitation or im-
munoblotting, cells were pelleted at 800Ug for 2 min, culture medium
was removed and the cells were resuspended and washed once in PBS.
The cell pellet was then resuspended by vigorous pipetting in ice-cold
NP-40 lysis bu¡er (0,5% NP-40, 50 mM Tris pH 7,4, 150 mM NaCl)
with 0,1% protease inhibitor cocktail (Sigma, St. Louis, MO, USA).
Lysis was continued for 20 min on ice and the lysates were cleared by
centrifugation at 15 000Ug for 10 min at 4‡C. The total protein con-
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centrations of the cleared lysates were determined using a modi¢ed
Lowry assay (Bio-Rad DC Protein Assay) with bovine serum albumin
as the standard.
For SDS^PAGE and immunoblotting, samples were diluted with
lysis bu¡er to balance the protein concentration and then SDS sample
bu¡er was added, followed by heating to 90‡C for 2 min. SDS^PAGE
was carried out using a 4% stacking gel and a 12% separation gel or a
pre-cast 4^20% gradient gel (Cambrex, Bio Science Rockland, Inc.,
Rockland, MA, USA). The proteins were blotted to Hybond-P
(Amersham Biosciences, Uppsala, Sweden) membranes using a semi-
dry blotting apparatus with a discontinuous bu¡er system [4] at room
temperature (RT). The membranes were blocked in Tris-bu¡ered sa-
line (TBS) containing 5% dry skim milk (TBSS) and 1% Tween 20 for
45 min at RT. Hybond-P membranes were cut in slices and incubated
with primary antibody diluted in TBSS for 1 h at RT in separate
trays, washed three times for 10 min each in TBS and incubated
with the goat secondary horseradish peroxidase-conjugated antibody
for 1 h at RT and ¢nally washed as above. Hybond-P slices were then
aligned and the immunoreactivity was visualised using enhanced
chemiluminescence (ECL, Amersham Biosciences) followed by expo-
sure to either standard X-ray ¢lm (AGFA) or to Hyper¢lm (Amer-
sham Biosciences).
2.3. Immunoprecipitation
Prior to immunoprecipitation, the clone 22 antibody was pre-ad-
sorbed to protein-G Sepharose using 4 Wg of antibody per 40 Wl of
pre-washed protein-G Sepharose slurry for 1 h at 4‡C, and washed
three times in 1 ml of lysis bu¡er. The lysates to be used for immu-
noprecipitation were pre-adsorbed with protein-G Sepharose at 4‡C
for 1 h, and then incubated with the antibody - protein-G Sepharose
complexes in a total volume of 1 ml over-night at 4‡C The beads were
¢nally washed four times in 1 ml of lysis bu¡er, and eluted in a small
volume of SDS sample bu¡er by heating to 90‡C for 2 min. The
eluted proteins were collected in the supernatant after centrifugation
at 15 000Ug for 5 min, and loaded onto an SDS gel. Following Coo-
massie Brilliant Blue G staining the bands were cut out, and prepared
for matrix assisted laser desorption ionisation time of £ight mass
spectrometry (MALDI-TOF-MS).
2.4. In-gel trypsin digestion and MS-analysis
Protein bands were in-gel digested with minor modi¢cations of the
protocol by Shevchenko et al., [5]. Excised bands were destained by
washing in 25 mM ammonium bicarbonate in 50% acetonitrile. After
dehydration using 200 Wl of acetonitrile, the samples were reduced
with 10 mM DTT in 50 mM ammonium carbonate for 30 min at
56‡C. Following dehydration as above the proteins were alkylated
using 200 Wl of 55 mM iodoacetamide in 50 mM ammonium carbon-
ate for 30 min. Then the samples were dehydrated in 200 Wl of ace-
tonitrile and dried in a Speed Vac for 10 min. Samples were rehy-
drated by addition of 15 Wl of 50 mM ammonium bicarbonate with 10
ng/Wl of porcine modi¢ed trypsin for 15 min, then 10 Wl of 50 mM
ammonium carbonate were added, and the samples incubated at 37‡C
over night. Samples were acidi¢ed by adding 5 Wl of 10% TFA and
incubated 10 min. Extracted peptides were removed and 100 Wl of 60%
acetonitrile were added to the gel slices. After 30 min incubation the
supernatants were combined and the acetonitrile removed by lyophi-
lisation. Samples of 10 Wl were puri¢ed using W-ZipTips, and the pep-
tides were eluted in 50% of a 1 g/l of K-cyano-4-hydroxycinnamic acid
in 0,1% TFA and 50% acetonitrile. 1.5 Wl was spotted directly to a
Bruker Anchorchip target (400 Wm) and analysed on a Bruker Ultra-
Flex (Bruker Daltonics Inc., Billerica, USA). External calibration was
done using peptide standards from Bruker Daltonics Inc. MS/MS
spectra were acquired on selected peptides using the MS/MS capabil-
ities of the Ultra£ex instrument. The peptide mass ¢ngerprint and the
MS/MS spectra were searched against the non-redundant MSDB da-
tabase using Mascot (MatrixScience, London, United Kingdom).
3. Results
3.1. Immunoprecipitation of p23 using the clone 22 anti ALG-2
antibody
Recently, we reported that the clone 22 antibody did not
recognise ALG-2, but a protein that appeared 1^2 kDa larger
than endogenous human ALG-2 and recombinant murine
ALG-2, as estimated following SDS^PAGE and immunoblot-
ting [1]. In order to identify the antigen recognised by the
clone 22 antibody we tested whether this IgG1 antibody was
suitable for immunoprecipitation from lysates of exponen-
tially growing Jurkat-E6 cells and from lysates of Jurkat-E6
cells induced to undergo apoptosis by CD95 receptor cross-
linking. The monoclonal antibody did speci¢cally precipitate
proteins, which were visualised by Coomassie staining of an
SDS^polyacrylamide gel (Fig. 1, lanes 3 and 4). We observed
that the signal intensity of a 23 kDa protein precipitated from
the apoptotic Jurkat-E6 cell lysate was decreased (Fig. 1, band
D) as compared to that from the non-apoptotic cells (Fig. 1,
band B). Moreover, two additional bands of approximately 22
kDa (Fig. 1, band E) and 40 kDa (Fig. 1, band C), respec-
tively, were precipitated from the apoptotic cell lysates. Im-
munoprecipitation with a p23 unrelated IgG1 antibody (anti-
Fas/CD95/APO-1, clone 13) from the non-apoptotic Jurkat-
E6 lysate did not reveal any bands below 25 kDa (Fig. 1, lane
5).
In order to identify the immunoprecipitated proteins the
bands designated A^E were cut from the gel and analysed
by tryptic in-gel digestion followed by MALDI-TOF-MS
and MS/MS analysis of the peptides (Fig. 2). The internal
control (Fig. 1, band A) was correctly assigned as murine
ALG-2. Band C (Fig. 1) was identi¢ed as the human hetero-
geneous ribonuclear protein A2/B1 (hnRNPA2/B1), and
bands B, D, and E (Fig. 1) were all identi¢ed as the human
progesterone receptor-related protein p23, also named human
telomerase binding protein p23, or HSP90 co-chaperone p23
(Fig. 2). Peptides from bands B and E (Fig. 1) were further
veri¢ed by MS/MS sequencing and were con¢rmed to derive
from p23 (results are summarised in Table 1). These data
provide evidence that the clone 22 antibody speci¢cally pre-
cipitates p23 but not ALG-2 from non-apoptotic and apopto-
Fig. 1. Speci¢c immunoprecipitation of the co-chaperone p23 pro-
tein using the BD clone 22 anti-ALG-2 antibody from non-apopto-
tic and apoptotic Jurkat-E6 cell lysates. Apoptosis was induced for
4 h using the APO-1-3 antibody. The lanes of this Coomassie
stained SDS gel represent: protein molecular weight marker (1), re-
combinant murine ALG-2 (2), immunoprecipitation from non-apo-
ptotic lysate (3), immunoprecipitation from apoptotic lysate (4), im-
munoprecipitation using the clone 13 anti-CD95 antibody from
non-apoptotic lysate (5) The gel is representative of three separate
experiments.
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tic Jurkat-E6 cells. Therefore, the previously published data
on ALG-2 using the clone 22 antibody [6^11] have to be
corrected since the investigated protein was indeed the
HSP90 co-chaperone protein p23. Furthermore, our data in-
dicate that p23 is cleaved following apoptosis induction by
CD95 receptor cross-linking in Jurkat-E6 cells releasing a
product of about 22 kDa.
3.2. hnRNPA2/B1 co-immunoprecipitates with p23
The MS-analysis revealed that the clone 22 antibody
co-immunoprecipitated hnRNPA2/B1 from the apoptotic
Jurkat-E6 cells (Fig. 1, band C). This indicates that p23 is
in a complex with the RNA binding protein hnRNPA2/B1.
Since immunoprecipitation cannot be considered a quanti-
tative method this does not provide evidence that the p23^
hnRNPA2/B1 interaction is speci¢c for apoptosis. hnRNPA-
2/B1 is involved in splicing and transport of mRNA (see [12])
and it is able to bind to telomeric repeats [13]. A model has
been proposed, in which hnRNPs in a complex with the telo-
merase holoenzyme, HSP90/p23 and other co-factors, is in-
volved in telomere and telomerase regulation [14]. The co-im-
munoprecipitation of hnRNPA2/B1 and p23, therefore,
supports the existence of such a complex.
3.3. p23 is cleaved following apoptosis induction in Jurkat-E6
cells
Treatment of Jurkat-E6 cells with an agonistic anti-CD95
antibody [15] and 10 ng/ml of protein A for 2 h induced severe
membrane blebbing and nuclear fragmentation (data not
shown), which are hallmarks of apoptosis. To analyse whether
the clone 22 antibody would also detect the cleaved p23 in
immunoblots and not ALG-2, we compared this antibody
with other p23 antibodies and with our two polyclonal anti-
ALG-2 antibodies. Fig. 3A shows that the BD clone 22 anti-
body, the BD clone 16 mouse monoclonal p23 antibody and
the p23 clone JJ3 antibody [16] all detect full-length p23 from
non-apoptotic Jurkat-E6 lysates and they recognise the full-
length p23 and the truncated p23 from the apoptotic Jurkat-
E6 lysates. The clone 16 antibody also detects a band around
40 kDa with unknown identity (Fig. 3A). The two anti-ALG-
2 antibodies only recognised a single band at 22 kDa in both
non-apoptotic and apoptotic Jurkat-E6 lysates (Fig. 3B),
which strongly suggests that ALG-2 is not proteolytically de-
graded following apoptosis induction by CD95 cross-linking.
The data give further support for the speci¢city of the clone
22 antibody, and also show that truncated p23 can be detected
by immunoblotting with other p23 antibodies.
4. Discussion
In this paper we show that the BD clone 22 antibody does
not recognise ALG-2, but speci¢cally recognises the HSP90
co-chaperone p23. Unfortunately, the clone 22 antibody has
been used by several groups to describe properties of ALG-2.
These data have to be revised in the light of our new data.
However, the work previously done with the clone 22 anti-
body signi¢cantly contributes to the understanding of novel
functions of p23.
Fig. 2. MALDI-TOF analysis of peptides from bands B and E (in-
dicated in Fig. 1). The immunoprecipitated proteins were separated
using SDS^PAGE and the Coomassie stained proteins were cut out
of the gel and in-gel trypsin digested. The labelled peaks identify
peptides of human HSP90 co-chaperone p23.
Table 1
Identi¢cation of peptides after in-gel tryptic digestion of bands A^E (see Fig. 1) by MALDI-TOF-MS
Band Accession
number
MS
coverage
MS/MS
residues
Protein name Gene
A P12815 85.9% ^ Mouse programmed cell death protein 6/apoptosis linked gene 2 (ALG-2) PDCD6
B Q15185 40.6% 36^48 Human progesterone receptor-related protein p23/HSP90 co-chaperone protein p23 TEBP
96^107
49^65
13^33
C P22626 49.6% ^ Human heterogeneous nuclear ribonucleoprotein A2/B1 ROA2
D Q15185 50.0% 36^48 Human progesterone receptor-related protein p23/HSP90 co-chaperone protein p23 TEBP
E Q15185 41.9% ^ Human progesterone receptor-related protein p23/HSP90 co-chaperone protein p23 TEBP
The MS coverage indicates the percentage of the protein that was identi¢ed by MS analysis alone. Peptide residues identi¢ed using MS/MS are
also listed.
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4.1. Increased expression of p23 after rat focal cerebral
ischemia
In an animal model of temporary focal ischemia, occlusion
of the rat right carotid artery for 20 or 90 min was used to
induce focal ischemia and this was followed by a reperfusion
period for up to 72 h [8]. Increased expression of p23 was
observed in the frontal cortex and in the parietal cortex within
24 h of reperfusion by both immunohistochemistry and im-
munoblotting using the clone 22 antibody. Double staining
revealed that p23 over-expression co-localised with DNA frag-
mentation. Interestingly, both COX isoforms (COX-1 and
COX-2) have been shown to be involved in the progression
of neuronal damage following ischemia [17]. The observed p23
up-regulation might contribute to increased PGE2 synthesis,
which is known to elevate the levels of free radicals leading to
oxidative damage. It remains to be investigated whether up-
regulation of p23 in ischemia leads to elevated PGE2 concen-
trations and whether p23 might be the rate-limiting factor.
4.2. p23 co-immunoprecipitates with CD95 and is cleaved in
apoptosis
Following apoptosis induction by CD95 crosslinking in Jur-
kat-E6 cells, p23 was co-precipitated with CD95 and was
shown to be cleaved using the clone 22 antibody [9]. p23
cleavage coincided with poly-ADP-ribose polymerase cleavage
assumed to be mediated by executioner caspases during apo-
ptotic cell death. This could indicate that p23 is a target for
these caspases. Using the clone 22 antibody in immunoprecip-
itation and immunoblotting experiments, we have con¢rmed
that apoptosis induction by CD95 cross-linking in Jurkat-E6
cells leads to the cleavage of p23 (Fig. 1 and 3). These obser-
vations point to a new link between apoptosis and the demise
of HSP90 chaperone client proteins which are dependent on
the HSP90 p23 co-chaperone complex to maintain their prop-
er function. HSP90 chaperone activity is needed for the cor-
rect folding and stability of several di¡erent signalling pro-
teins including multiple kinases and steroid receptors (see
[18]). Interestingly, it has also been demonstrated that the
PGE2 synthase activity of cPGES is regulated by HSP90 pro-
viding a link between the synthesis of PGE2 and a molecular
chaperone [19]. The chaperone functions of p23 are still not
known in details, but both passive chaperone activity of p23
itself [20] and HSP90 co-chaperone activity have been de-
scribed. The removal of p23 by proteolysis during apoptosis
may be part of the cooperative actions of the caspases that
leads to the well-de¢ned apoptotic phenotype.
4.3. Down-regulation of p23 in atherosclerotic plaques
A comparison between atherosclerotic human carotid en-
darterectomised specimens and non-atherosclerotic arteries
using a commercial Western blot array showed that the
down-regulation of the clone 22 antigen in the atherosclerotic
plaques was one of the most prominent di¡erences in protein
expression [11,28].
At the moment little is known about the biochemical pro-
cesses involved in atherosclerosis leading to myocardial infarc-
tion and stroke. In£ammation in the arterial wall plays a
crucial role in pathogenesis of myocardial infarction caused
by rupture of an atherosclerotic plaque. The anti-in£amma-
tory and anti-thrombotic drug aspirin, that inhibits COX 1
and prevents thromboxane A2 synthesis at the platelet-vessel
wall, is known to decrease the incidence of cardiovascular
disease (see [21]). The PGE2 production downstream of
COX-1 that is mediated by p23 could have an important
role. Severe down-regulation of p23 could lead to an disturbed
balance between the PGH2 metabolising enzymes and a
changed prostanoid status, eventually towards a pathogenic
situation. Further investigation of the role of p23 should be
conducted in order to understand the role of p23 in athero-
sclerosis, especially in the light of the central enzymatic role of
p23 as one of the two known PGE2 synthases. Since massive
apoptosis in the atherosclerotic plaques has been described
(see [22]), it is likely that the low level of p23 is the result
of caspase activity in the plaques. However, down-regulation
of p23 could also be a trigger of apoptosis.
4.4. PYK2
In a study of the interaction between ALG-2 binding pro-
Fig. 3. The co-chaperone p23 is cleaved following CD95 cross-link-
ing in Jurkat-E6 cells. A: Immunoblot of control (non-apoptotic)
and apoptotic Jurkat-E6 cell lysates prepared after 4 h of apoptosis
induction. The BD anti-ALG-2 clone 22, the BD anti-p23 clone 16,
and the anti-p23 clone JJ3 antibodies were diluted 5000, 1000, and
1000 times, respectively. The immunoblot is representative of two
separate experiments. B: Immunoblot of control (non-apoptotic)
and apoptotic Jurkat-E6 cell lysates prepared after 2 h of apoptosis
induction. The BD clone 22 antibody in lanes 1 and 2, is diluted
3000 and 5000 times, respectively, The a⁄nity puri¢ed rabbit anti-
recombinant ALG-2 antibody in lane 3, and the a⁄nity puri¢ed
rabbit anti-peptide antibody in lanes 4 and 5, are diluted 1000, 500,
and 200 times, respectively. The immunoblot is representative of
four separate experiments.
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tein 1 (AIP1) and a protein expressed in tumourigenic astro-
cytes (SETA) [10], it was found that the focal adhesion kinase
2 (FAK-2 or PYK2) can be co-immunoprecipitated with the
clone 22 antigen. Since p23 is a HSP90 co-chaperone, PYK2
should be added to the growing list of HSP90 chaperone
complex client proteins, which also includes several important
signalling kinases.
4.5. Over-expression of p23 in cancer tissue
By comparison of normal tissue and adjacent malignant
tissue of mammary carcinomas as well as metastases, it was
reported using the clone 22 antibody that the antigen expres-
sion was low or absent in normal tissue, increased in the
primary tumour and strongly up-regulated in the metastases
[7].
Recent studies have shown that COX-1 is up-regulated in
several human cancers, including breast [23], prostate [24] and
ovarian cancer [25], as well as in cervical carcinomas [26]. In a
mouse model of a highly metastatic mammary carcinoma, the
oral intake of either selective COX-1 inhibitors or COX-2
inhibitors resulted in signi¢cant inhibition of tumour growth
[27]. Elevated synthesis of PGE2 has been shown to induce a
malignant phenotype with an increased metastatic potential of
epithelial cells, to inhibit apoptosis, and to promote angio-
genesis (see[26]). Therefore, the observed up-regulation of
p23 in malignant tissue, suggests that the inhibition at the
level of the COXs, could be improved by more speci¢c target-
ing of p23.
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